Medicines Distribution Consent




22 JUNE NEW ZEALAND GAZETTE 1487

Product:
Captohexal
Active Ingredient(s):
Captopril 25mg
Dosage Form:
Tablet
New Zealand Sponsor:
Hexal New Zealand Limited
Manufacturer(s):
Hexal-Pharma GmbH, Holzkirchen, Germany

Product:
Captohexal
Active Ingredient(s):
Captopril 50mg
Dosage Form:
Tablet
New Zealand Sponsor:
Hexal New Zealand Limited
Manufacturer(s):
Hexal-Pharma GmbH, Holzkirchen, Germany

Product:
Hycamtin
Active Ingredient(s):
Topotecan hydrochloride 1.24mg equivalent to 1.1mg topotecan free base
Dosage Form:
Powder for infusion
New Zealand Sponsor:
SmithKline Beecham (NZ) Limited
Manufacturer(s):
SmithKline Beecham Pharmaceuticals, Conshohocken, Pennsylvania, United States of America

Product:
Invicorp 1 Autoinjector
Active Ingredient(s):
Phentolamine mesylate 1mg
Vasoactive intestinal polypeptide 25µg
Dosage Form:
Solution for injection
New Zealand Sponsor:
Saltarelo Holdings Limited
Manufacturer(s):
Novocol Pharmaceuticals of Canada Inc., Cambridge, Ontario, Canada

Product:
Invicorp 1
Active Ingredient(s):
Phentolamine mesylate 1mg
Vasoactive intestinal polypeptide 25µg
Dosage Form:
Solution for injection
New Zealand Sponsor:
Saltarelo Holdings Limited
Manufacturer(s):
Medeva Pharma Limited, Vale of Bardsley, Ashton-Under-Lyne, Lancashire, England

Product:
Invicorp 2 Autoinjector
Active Ingredient(s):
Phentolamine mesylate 2mg
Vasoactive intestinal polypeptide 25µg
Dosage Form:
Solution for injection
New Zealand Sponsor:
Saltarelo Holdings Limited
Manufacturer(s):
Novocol Pharmaceuticals of Canada Inc., Cambridge, Ontario, Canada

Product:
Invicorp 2
Active Ingredient(s):
Phentolamine mesylate 2mg
Vasoactive intestinal polypeptide 25µg
Dosage Form:
Solution for injection
New Zealand Sponsor:
Saltarelo Holdings Limited
Manufacturer(s):
Medeva Pharma Limited, Vale of Bardsley, Ashton-Under-Lyne, Lancashire, England

Dated this 14th day of June 2000.

G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go4419

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:

Schedule

Product:
Synercid
Active Ingredient(s):
Dalfopristin 350mg
Quinupristin 150mg
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Aventis Pharma Limited
Manufacturer(s):
Catalytica Pharmaceuticals Inc, Greenville, North Carolina, United States of America

Note: This consent is valid for 2 years from the date of publication of this notice.

Dated this 14th day of June 2000.

G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go4418



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2000, No 67


Gazette.govt.nz PDF NZ Gazette 2000, No 67





✨ LLM interpretation of page content

🏥 Consent to the Distribution of New Medicines (continued from previous page)

🏥 Health & Social Welfare
14 June 2000
Medicines, Distribution, Captohexal, Hycamtin, Invicorp, Synercid
  • G. R. Boyd, Chief Advisor, Safety and Regulation